RxDoctor Payments DataLook up a doctor →

Pradeep Nair, MD

Interventional Cardiology · Houma, LANPI 1659517670

Payments from drug & device makers

$220,371in general payments, 2019–2025

Across 503 payments — averaging $438.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$87K
  • Surmodics, Inc.$55K
  • Boston Scientific$22K
  • Cardiovascular Systems Inc.$13K
  • Angiodynamics, Inc.$9K
  • Abbott$8K
  • plus $26K from 44 others
$4,200in research payments, 2019–2025

Across 1 payment — averaging $4200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$4K

What the payments were for

  • Consulting fees$137,61365%
  • Speaking & faculty fees$32,07515%
  • Travel & lodging$15,4707%
  • Food & beverage$20,38210%
  • Education$4320%
  • Other$6,4003%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$220,371 in reported general payments places this provider in the 90th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$710,748
Medicare patients
783
Services billed
5,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$335,376
VyndamaxTafamidis11$285,696
XareltoRivaroxaban386$275,118
Repatha SureclickEvolocumab125$90,320
BrilintaTicagrelor110$69,615
EntrestoSacubitril/Valsartan43$44,379
JardianceEmpagliflozin19$21,699
Praluent PenAlirocumab32$17,146
FarxigaDapagliflozin Propanediol15$14,093
ClopidogrelClopidogrel Bisulfate1,012$10,245
VascepaIcosapent Ethyl16$8,158
Atorvastatin Calcium761$6,469
Metoprolol Succinate425$5,335
Rosuvastatin Calcium396$5,112
Ezetimibe254$4,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$88$621,072353 claims
Johnson & JohnsonXarelto$863$275,118386 claims
AstraZenecaBrilinta, Farxiga$125$83,708125 claims
NovartisEntresto$34$44,37943 claims
Boehringer IngelheimJardiance$14$21,69919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Houma

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →